A CHAMIGRENIC COMPOUND AS A NAEGLERIA FOWLERI INFECTION TREATMENT.

Patent number:

P202230496

No items found.

The invention discloses the use of a sesquiterpene compound for the treatment or prevention of primary amebic meningoencephalitis (PAM) caused by Naegleria fowleri in a human or animal subject, preferably of the compound (+)- elatol, and the pharmaceutical composition containing said compound.

Countries:

Spain

Regions:

Canary Islands

Centers:

UNIVERSIDAD DE LA LAGUNA

Other entities:

Universidad Federal de Río de Janeiro

Sectors:

Chemicals

Subsectors:

TRL Level:

TRL 3 – experimental proof of concept

BRL Level:

PDF Link:

Download here

Video Link:

Watch it here

Sustainable Development Goal:

SDG03: Good health and well-being

Applications

High selectivity index Low toxicity values Alternative to existing treatments Treatment of diseases caused by "brain-eating amoeba"

Comments

Other related patents

Chemicals

New & Sustainable Materials

BIO-BASED INORGANIC-ORGANIC MATERIALS

Countries

Spain

Chemicals

DEVICE FOR THE DETECTION OF FORMALDEHYDE

Countries

Spain

Chemicals

Antioxidant aqueous extracts of plant raw materials, method for obtaining same and the use thereof in the composition of a cosmetic product.

Countries

Spain

Get back to patents directory